The Product

Designing patient-specific drug combinations

PNX is a diagnostic test based on information-theoretic analysis of proteomic data that predicts the optimal personalized treatment combination in patients suffering from cancer, according to their specific protein network “barcode”.

MEDPNC’s chief scientist, Dr. Kravchenko-Balasha has found in her research that 3,467 tumors can be described by just 17 unbalanced processes, and that each tumor results from a combination of two to three of these processes. Based on this research, MEDPNC has developed a purpose-built treatment strategy algorithm based on the information-theoretic approach. This development simplifies the detection of unbalanced protein networks in the patient and creates a personalized “barcode“ that is capable of predicting the efficacy of various treatment options as well as recommending the optimal combination, thus increasing life expectancy.

 

How Does it Work?

Sample Acquisition

Patient-Specific
Proteomic Profiling
0
pEGFR
0
pEGFR
0
P53
0
S6K
0
MAPK14
0
pAkt
0
pMer2
0
pPDGFRa

Suprisal Analysis
Identifies unbalanced molecular processes

Identification
Patient-Explicit Barcodes

Prediction and Validation
of optimal targets for therapy

Patient Tailored
Combination Therapy

Personalized Combination Therapy
targeting distinct cancer processes in each individual malignancy
may be an essential key to curing cancer